Single-Center, Double-Blind, Placebo-Controlled, Single-Dose, 4-Period Crossover, Drug-Alcohol Interaction Study in Lemborexant in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2018
At a glance
- Drugs Lemborexant (Primary) ; Alcohol
- Indications Circadian rhythm sleep disorders; Insomnia; Sleep apnoea syndrome
- Focus Pharmacodynamics
- Sponsors Eisai Inc
- 27 Jul 2018 Last checked against ClinicalTrials.gov record.
- 19 Jul 2018 Planned End Date changed from 18 Jun 2018 to 12 Sep 2018.
- 19 Jul 2018 Planned primary completion date changed from 18 Jun 2018 to 12 Sep 2018.